← Back to Search

Xanthine Oxidase Inhibitor

Safety/Efficacy Study to Evaluate of MBX-102 in Combination With Allopurinol in Gout Patients

Phase 2
Waitlist Available
Research Sponsored by Gilead Sciences
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up percent change from baseline in serum uric acid at week 4
Awards & highlights
Approved for 10 Other Conditions

Summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of MBX-102 in combination with allopurinol compared to allopurinol alone when administered orally once a day for four weeks to gout patients with an inadequate hypouricemic response to allopurinol alone.

Eligible Conditions
  • Gout

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~percent change from baseline in serum uric acid at week 4
This trial's timeline: 3 weeks for screening, Varies for treatment, and percent change from baseline in serum uric acid at week 4 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Serum Uric Acid

Awards & Highlights

Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Group I: Arhalofenate 600 mgExperimental Treatment3 Interventions
Arhalofenate 600 mg plus allopurinol 300 mg
Group II: Arhalofenate 400 mgExperimental Treatment3 Interventions
Arhalofenate 400 mg plus allopurinol 300 mg
Group III: AllopurinolActive Control3 Interventions
Placebo plus Allopurinol 300 mg
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Allopurinol
FDA approved
Arhalofenate
Not yet FDA approved
Colchicine
FDA approved

Find a Location

Who is running the clinical trial?

Gilead SciencesLead Sponsor
1,137 Previous Clinical Trials
867,922 Total Patients Enrolled
4 Trials studying Gout
374 Patients Enrolled for Gout
CymaBay Therapeutics, Inc.Lead Sponsor
22 Previous Clinical Trials
3,156 Total Patients Enrolled
4 Trials studying Gout
374 Patients Enrolled for Gout
~7 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top